Form D · Biotechnology
MABCURE INC.
Hasselt, C9 · CIK 0001388490
Offering snapshot reported Jan 24, 2011 · SEC filing
- Reported sold
- $315K Offering amount: $315K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $315K Reported outside-investor minimum
- First sale
- Jan 18, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 24, 2011 | Initial | $315,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Debt, Security to be acquired
- Exemptions
- 06, 46
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $8K
- Form D file number
- 021-154237
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Midsouth Capital, Inc. | 35039 |
Source: Form D, filed Jan 24, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gad Berdugo | Director |
| David Frank | Director |
| Amnon Gonenne | Director, Executive |
| Ron Kalfus | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
De Schiervellaan 3/B1
Hasselt, C9, 3500
Hasselt, C9, 3500